The major goal of this Project are to identify antigens characteristics of epithelial ovarian cancer (EOC) using mouse monoclonal antibodies (mAbs) and to study some aspects of the biology of ovarian epithelium and its malignant transformation. The antigens detected by the mAbs will be characterized using biochemical and molecular approaches. An important aim will be to identify mAbs that are suitable for use in clinical trials involving EOC. Among mAbs to be studied are mAb MX35 (detecting a 95,000 glycoprotein), mAbs VK-5, 6, and 7 (detecting the MUC-1 mucin epitope), mAb MW 207 (detecting folate-binding protein) and mAb VK-8 (detecting a novel EOC antigen). This Project will also test chimeric and humanized versions of an anti-blood group Le antibody for their specificity and other parameters. Another goal will be to use various mAbs to detect markers related to the progression of normal ovarian epithelium to EOC and markers suitable for the classification of ovarian tumors. Three types of antigens will be examined: 1) blood group antigens, 2) ectopeptidases, and 3) mucins. Mucins will be studied in more detail using biochemical and molecular techniques in order to understand the role played by mucins in EOC. Also, novel methods for the analysis of the carbohydrate content of glycoproteins and mucins will be developed. The accomplishment of theses goals will provide new reagents for the diagnosis and therapy of EOC and will lead to an understanding of the antigenic changes associated with the malignant transformation of normal ovarian epithelium, tumor progression, and the biological behavior of ovarian tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA052477-07
Application #
6237133
Study Section
Project Start
1997-02-01
Project End
1998-09-29
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
7
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Grisham, Rachel N; Sylvester, Brooke E; Won, Helen et al. (2015) Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. J Clin Oncol 33:4099-105
Rao, Thapi D; Tian, Huasong; Ma, Xun et al. (2015) Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS One 10:e0126633
Tew, William P; Colombo, Nicoletta; Ray-Coquard, Isabelle et al. (2014) Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 120:335-43
Tsuji, Takemasa; Sabbatini, Paul; Jungbluth, Achim A et al. (2013) Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 1:340-50
Soslow, Robert A; Han, Guangming; Park, Kay J et al. (2012) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25:625-36
Blixt, Ola; Lavrova, Olga I; Mazurov, Dmitriy V et al. (2012) Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells. Glycobiology 22:529-42
Gardner, Ginger J; Baser, Raymond E; Brady, Mark F et al. (2012) CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol 124:216-20
Hyman, David M; Long, Kara C; Tanner, Edward J et al. (2012) Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol Oncol 126:224-8
Hyman, David M; Zhou, Qin; Iasonos, Alexia et al. (2012) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118:3703-9
Marchini, Sergio; Poynor, Elizabeth; Barakat, Richard R et al. (2012) The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res 18:4313-24

Showing the most recent 10 out of 109 publications